Sixth UCLH patient to receive innovative drug for CJD
A sixth patient of University College London Hospitals NHS Foundation Trust (UCLH) is receiving an innovative treatment for Creutzfeldt-Jakob disease (CJD).
In October 2018, we began treating patients with an unlicensed antibody called PRN100 which has been developed by researchers at the Medical Research Council (MRC) Prion Unit at University College London (UCL).
CJD is an invariably, and usually rapidly, fatal disease. Four of the six patients we have treated with the drug have sadly now died as a result of their condition.
For further information please visit: